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V. Veerappan5, C.S. Bolmall1
1Glenmark Pharmaceuticals Ltd, Mumbai, India; 2Sujay Hosp. and Upadhyay
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Purpose: A new Diacerein Modiﬁed - Release (MR) formulation has been
developed in India. The present prospective, randomized, double blind,
multicentric, comparative study was undertaken to evaluate eﬃcacy, safety
and tolerability of Diacerein MR 100mg and conventional Diacerein 50mg
in 224 adult patients with Osteoarthritis(OA) of the Knee after approval by
the respective institutional ethics committee.
Methods: Patients fulﬁlling selection criteria were treated with Diacerein
MR 100mg once daily or Diacerein 50mg twice daily for 8 weeks after
obtaining their informed consent. The primary eﬃcacy variables included
Improvement in Western Ontario and McMasters (WOMAC) individual
osteoarthritis (OA) indices and Composite Index (for pain, stiffness and
physical function) and the Visual Analog Scale (VAS) scores (for pain) while
the secondary variable included improvement in Patient’s and Physician’s
Global Assessment of Arthritis.
Results: Seven patients in Diacerein MR and 8 in Diacerein group were
lost to follow up. Thus a total 105 patients in Diacerein MR 100mg group
and 106 in Diacerein 50mg group were included in the analysis. Results
indicated that there was a statistically signiﬁcant(p<0.05) early reduction
in the mean VAS scores, WOMAC-OA pain, stiffness and physical function
scores in both the groups at the end of 8 weeks. The reduction in mean
total score of WOMAC - OA was signiﬁcantly (P<0.05) greater in Diacerein
MR group as compared to Diacerein group at the end of the study. A greater
number of patients in Diacerein MR group had good to very good effects
of treatment and the difference was statistically signiﬁcant (P<0.05) as per
both patients and physicians global assessment as compared to Diacerein
group. The incidence of diarrhea was less in Diacerein MR group compared
to Diacerein group.
Conclusions: Once-daily Diacerein MR 100 mg was as effective as twice
daily Diacerein 50 mg but better tolerated and could be a valuable
therapeutic option in patients with osteoarthritis of the knee.
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Purpose: A sustained release (SR) formulation of Lornoxicam has been
developed and permits once-daily dosing in the symptomatic relief of
patients with osteoarthritis. The present randomized, double-blind com-
parative multicentric(4) study was undertaken to compare the effectiveness
and tolerability of SR lornoxicam 16mg once daily and conventional lornoxi-
cam 8mg twice daily in adult Indian patients with osteoarthritis of the
knee.
Methods: The present study was approved by the institutional ethics com-
mittee and patients fulﬁlling the selection criteria were treated with either
SR lornoxicam 16mg once daily or conventional lornoxicam 8mg twice
daily for eight weeks after obtaining their informed consent. The primary
endpoints were Western Ontario and McMasters (WOMAC) individual
osteoarthritis (OA) indices and Composite Index (for pain, stiffness and
physical function) and Visual Analog Scale (VAS) scores (for pain).Safety
and tolerability were assessed at the end of the study through monitoring
adverse events and physical examination.
Results: Of the 219 patients enrolled in the study, seven (four in the
Lornoxicam SR and three in the conventional Lornoxicam group) were lost
to follow-up and were considered as dropouts. Over the 8-week study
period both drugs provided signiﬁcant (p<0.05) sustained relief of mean
pain score (WOMAC index), VAS pain score, scores of stiffness, physical
function and total WOMAC compared to baseline. However, the difference
in reduction between groups was not statistically signiﬁcant. Both the
formulations of lornoxicam were well tolerated with a comparable number
of patients 26.1% (28 of the 107) patients in the Lornoxicam SR group
and 29.5%(33 of the 112) patients in the lornoxicam conventional group
reporting gastrointestinal adverse events.
Conclusions: The present study suggested that once daily lornoxicam SR
had comparable eﬃcacy and tolerability as conventional lornoxicam twice
daily in the treatment of adult Indian patients with osteoarthritis of the
knee and could therefore be a suitable therapeutic option in this group of
patients by virtue of its once daily dosage regimen.
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Purpose: Osteoarthritis (OA) is a complex disease of the joints involving
subchondral bone, cartilage and synovium. Calcitonin (CT) due to its effects
on cartilage and bone metabolism, might be a potential therapeutic agent
for OA. As long-term administration of subcutaneous and intranasal salmon
CT (sCT) is hampered by local irritation and administration diﬃculties, a
convenient oral formulation of sCT using a 5-CNAC carrier (a molecule
based on Eligen® technology from Emisphere) was developed. Oral sCT
potentially treats OA by preventing or slowing articular cartilage destruc-
tion, reducing bone resorption and improving quality of subchondral bone.
Primary objective: To demonstrate the superiority of oral sCT to placebo
in preventing joint space narrowing of medial tibio-femoral knee joint and
reducing pain and functional disability in patients with knee OA. Secondary
objectives: To demonstrate effectiveness of oral sCT in the improvement
of stiffness and physical activity, global improvement of the patient’s
condition, prevention of knee cartilage degradation, measured by MRI, and
improvement of hand OA. Exploratory objectives: Analysis of biochemical
markers of cartilage and bone turnover. Safety objective: To demonstrate
safety and tolerability of oral sCT for treatment of OA.
Methods: In this multi-center, double-blind, placebo-controlled study, it
was planned to randomize 1150 patients with knee OA (aged 51-80 years)
to receive (1:1) oral sCT 0.8 mg twice daily or placebo for 24 months. Knee
joint space width (JSW) is measured by X-ray at screening and after 12 and
24 months of treatment. Knee pain, function and stiffness are measured by
WOMAC visual analogue scales (VAS) at screening, 1, 6, 12 and 24 months.
Additional VAS assessments of pain, physical activity and global disease
activity (by patient and physician). Knee cartilage volume and thickness
are derived from MRI, and radiographs of hands are taken in patients
with hand OA. Safety is assessed by adverse event incidence and changes
in laboratory proﬁles and monitored by an independent Data Monitoring
Committee (DMC). After interim analysis of 12 month eﬃcacy and safety
data for futility, the DMC concluded not to discontinue the study. Final
analysis of all eﬃcacy endpoints will be done after 24 months.
Results: This ongoing trial has completed recruitment of 1176 patients (age
64±6.6 years, 31.6% males and 68.4% females, BMI: 29.0±4.7) randomized
at 9 study sites in 6 countries till September 2008. Study results will be
available in late 2010.
Conclusions: This is a Phase III, randomized, placebo-controlled trial to
show the eﬃcacy and safety of oral sCT in patients with knee OA. A second
study of similar design is ongoing with 1020 OA patients in 10 countries.
